Phibro shares soared nearly 18% after strong Q4 results beat estimates, driven by growth from the Zoetis MFA acquisition and solid full-year performance.
Latest Ratings for PAHC
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 2022 | Barclays | Upgrades | Underweight | Equal-Weight |
| Nov 2021 | Morgan Stanley | Initiates Coverage On | Equal-Weight | |
| Jul 2021 | Barclays | Downgrades | Equal-Weight | Underweight |
